Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. As of 2022, the global psychedelics market was valued at $4.87 billion in the next six years. .” Why Is the Psychedelics Market Growing?

Therapy 109

Therapy Treatment Patients Policy 109

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 3, 2022

The Czech Republic legalized therapeutic cannabis for selected patients in 2015, and health insurance companies have been covering up to 90% of the cost of the treatment since 2020. According to official data cited by the Czech News Agency (CTK), the treatment helped improve the health condition and well-being of patients in 69% of cases.

Media 52

Media Chronic Pain Patients Treatment 52

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 14, 2022

Local governments may also impose zoning conditions on cannabis facilities, including but not limited to buffer zones, density conditions, hours of operation, odor control requirements, necessary operating permits, and storefront characteristics. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Veriheal

MAY 17, 2023

According to the 2022 Legislative Finance Committee Corrections Department Performance Report Card, about 35% of detentions in the state’s corrections department were for technical parole offenses. .” Ideally, people grappling with the effect of substance use disorder should be given treatment and assistance, not jailed.

Treatment 97

Treatment Policy Legislation Collective 97

Cannabis Law Report

MARCH 11, 2022

10 March 2022. The Technical Note “Management of Cannabis Waste in the context of activities that produce cannabis for medicinal purposes” was published on 8 February 2022. It became necessary to establish a legal framework to manage cannabis waste, in particular, its classification, transportation and treatment.

Medicine 52

Medicine Treatment Packaging Digestion 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time. Dr. Nick Allen, co-founder and CEO of Ksana Health, commented: “Psychedelic treatments are offering exciting new approaches to recovery from mental disorders.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

APRIL 21, 2022

and Canada highlights mounting cases of cannabis poisoning among pets and sheds new light on symptoms, treatments, and outcomes. Richard Quansah Amissah of the Ontario Veterinary College at the University of Guelph in Ontario, Canada, and colleagues present these findings in the open-access journal PLOS ONE on April 20, 2022.

Pets 52

Pets Research and Development Topical Consumption 52

Cannabis Law Report

AUGUST 24, 2022

25 August 2022. The data suggests we have seen a transition from illicit to legal use of medical cannabis, ” said lead researcher Professor Nicholas Lintzeris , from the Faculty of Medicine and Health at the University of Sydney. People using illicit products were more likely to be treating mental health or sleep conditions.

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

OCTOBER 22, 2021

Cybin’s Research and Development team has completed 74 in-vitro and in-vivo evaluations of Cybin’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions.

Research and Development 52

Research and Development Safety Media Data 52

Veriheal

DECEMBER 23, 2022

Dr. Maxwell’s team also collected data contained in samples sourced from California. After a close analysis of the data, the team determined that an absence of consistent federal guidelines regarding marijuana contaminants ultimately increases the risk of consumers developing health issues. 74 solvents. 21 microbes.

Research and Development 92

Research and Development Agriculture Data Extraction 92

Veriheal

DECEMBER 27, 2022

Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research. Psychedelics can also cause hallucinations, out-of-body experiences, and other changes in perception.

Research and Development 95

Research and Development Therapy Consumption DEA 95

Veriheal

JULY 29, 2022

. “Periods of lockdown during the COVID-19 pandemic drove increases in the use of cannabis in 2020,” reads the 2022 report, which highlighted how approximately 284 million people (equivalent to 5.6% Numerous other studies have also supported cannabis’ ability to alleviate, not worsen, mental conditions.

Legalization 99

Legalization Consumption Cannabis Cannabinoids 99

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules also create a pathway for Alternative Treatment Centers (ATC) previously licensed under New Jersey’s medical cannabis law to expand their operations to include recreational cannabis. New applicants may apply for either a conditional license or an annual license.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Fast Track review is for drugs that treat serious conditions and fill an unmet medical need. Defining Psychedelics. Approval Pathways.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 8, 2022

Published: Jun 07, 2022. MDMA-assisted therapy, a novel treatment for PTSD with FDA breakthrough therapy designation, is on track for NDA submission in 2023 pending results of the confirmatory Phase 3 trial. to serve on its Board of Directors, effective June 2, 2022. He holds a Ph.D. from Princeton University and a B.A.

Therapy 52

Therapy Treatment Access Patients 52

Cannabis Law Report

JULY 24, 2022

The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years [1]. The market research company Data Bridge Market Research projects that the market capitalization of the psychedelic industry will grow 16.8 billion by 2029.

Research and Development 52

Research and Development Legalization Treatment Patients 52

Veriheal

AUGUST 9, 2023

In contrast, a more significant proportion, 76%, recognized addiction as a medical condition, demonstrating increased understanding and compassion towards those facing such challenges. Equally, 76% believed that addiction is preventable and treatable, underscoring the value of early intervention and treatment programs.

Education 98

Education Vaping Cannabis Consumption 98

The Cannigma

AUGUST 5, 2022

Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment? Ketamine treatment for depression may be one of the biggest leaps forward in mental healthcare in decades.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. He added that significant data is still needed to inform policy regarding use of consumer cannabis products. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D.

Pets 105

Pets Hemp CBD Food 105

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. A month later, on May 16, the Department of Health and Human Services approved the FDA’s Epidiolex recommendation. will top $1.9 John’s wort. will top $1.9

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Interim efficacy analysis from this study is expected in the first quarter of 2022. Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. in the blood. is the master regulator of inflammation, MYMD-1’s function as a TNF-?

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Project CBD

JUNE 20, 2023

Food and Drug Administration, three are prescribed for the treatment of chemotherapy-induced nausea and vomiting. One gastrointestinal condition long associated with self-medication through cannabis is inflammatory bowel disease (IBD). As of March 2022, approximately 120,000 patients were registered in the program.

Cannabinoids 208

Cannabinoids Patients Treatment Conditions 208

Veriheal

JANUARY 5, 2022

Despite the restrictions on research as a result of the Schedule I classification of cannabis, researchers have made many remarkable strides in proving the efficacy and safety of cannabis on the aforementioned conditions. . While Biden is receiving a lot of heat as a result of his inaction, many feel it is deserved.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

MAY 19, 2022

FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. CBD oil is an effective natural treatment for OCD.”. “If The agency cites a lack of data on the potential residues of these substances that would reach the human consumer.

THC 52

THC CBD Food Pets 52

Project CBD

FEBRUARY 27, 2023

In the absence of an answer — or a cure — treatment is the name of the game for fibromyalgia. Recently published papers — a series of reviews, two human studies, and an animal study — only bolster the case that cannabis can help those suffering from this confounding condition.

THC 144

THC CBD Sleep Clinical Trials 144

Cannabis Law Report

MAY 6, 2022

May 6, 2022. At this time the FDA has not evaluated what, if anything, these products are effective for and what appropriate doses might be, or whether there are counterindications for persons taking other drugs or having any other health conditions. Delta-8 is known to be successful in many cancer treatments.”. Michelle R.E.

THC 52

THC CBD Media Food 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. 2020;12(7):1935.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

CannaTech

OCTOBER 14, 2018

Similar conditions in the Imperial Valley of extreme southern California have permitted cultivators like Farmtiva to thrive as the company operates an industrial hemp research and grow facility on 160 acres of a former U.S. billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA. in thousands, except share data). . . . India Globalization Capital, Inc.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help. A primary headache, such as a migraine, is its own condition, and not caused by a separate condition.

Terpenes 132

Terpenes Strains THC Treatment 132